Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
$6.01
+14.0%
$4.08
$0.64
$6.26
$24.04M0.46150,445 shs327,064 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.45
+1.4%
$1.52
$0.94
$1.92
$23.30M1.15232,097 shs85,167 shs
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
$1.20
+22.8%
$1.08
$0.55
$1,200.00
$5.86MN/A267,446 shs39.82 million shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.93
+2.7%
$1.96
$1.35
$53.17
$23.54M0.0780,906 shs58,222 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
0.00%+31.51%+54.10%+427.19%+210.87%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00%-2.68%-1.36%-3.97%-11.04%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
0.00%+17.65%+7.14%+43.71%+119,999,900.00%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
0.00%+15.57%+2.66%+15.57%-96.12%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
$6.01
+14.0%
$4.08
$0.64
$6.26
$24.04M0.46150,445 shs327,064 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.45
+1.4%
$1.52
$0.94
$1.92
$23.30M1.15232,097 shs85,167 shs
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
$1.20
+22.8%
$1.08
$0.55
$1,200.00
$5.86MN/A267,446 shs39.82 million shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.93
+2.7%
$1.96
$1.35
$53.17
$23.54M0.0780,906 shs58,222 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
0.00%+31.51%+54.10%+427.19%+210.87%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00%-2.68%-1.36%-3.97%-11.04%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
0.00%+17.65%+7.14%+43.71%+119,999,900.00%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
0.00%+15.57%+2.66%+15.57%-96.12%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
0.00
N/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00
N/AN/AN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
0.00
N/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.25
Hold$12.17530.40% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/AN/AN/AN/A($1.19) per shareN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/A$0.66 per shareN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/AN/A$315.05 per shareN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/A$0.47 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
-$3.59M-$1.29N/AN/AN/AN/A-222.90%11/10/2025 (Estimated)
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-$8.29M-$0.70N/AN/AN/A-87.90%-78.69%N/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
-$1.54MN/A0.00N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$47.73M-$4.30N/AN/AN/AN/A-2,709.70%-61.16%11/6/2025 (Estimated)

Latest PLRZ, LIXT, NNVC, and QTTB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/A-$0.29N/A-$0.29N/AN/A
8/6/2025Q2 2025
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$1.14-$0.78+$0.36-$0.78N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/AN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
N/A
1.84
1.84
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/A
3.44
2.47
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A
10.16
10.16
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
1.68
5.06
5.06

Institutional Ownership

CompanyInstitutional Ownership
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
5.10%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
10.30%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
31.32%

Insider Ownership

CompanyInsider Ownership
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
14.80%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
4.60%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
40.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lixte Biotechnology Holdings, Inc. stock logo
LIXT
Lixte Biotechnology
44.56 million3.89 millionNot Optionable
NanoViricides, Inc. stock logo
NNVC
NanoViricides
2016.07 million14.92 millionOptionable
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A5.99 millionN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
3912.20 million7.32 millionN/A

Recent News About These Companies

Q32 Bio (QTTB) Q2 Loss Drops 45%
Leerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)
Q32 Bio price target lowered to $15 from $16 at Wells Fargo
Q32 Bio: Q4 Earnings Snapshot
Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lixte Biotechnology stock logo

Lixte Biotechnology NASDAQ:LIXT

$6.01 +0.74 (+14.04%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$6.04 +0.03 (+0.50%)
As of 09/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

NanoViricides stock logo

NanoViricides NYSE:NNVC

$1.45 +0.02 (+1.40%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$1.45 0.00 (0.00%)
As of 09/12/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Polyrizon stock logo

Polyrizon NASDAQ:PLRZ

$1.20 +0.22 (+22.76%)
As of 09/12/2025 04:00 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

Q32 Bio stock logo

Q32 Bio NASDAQ:QTTB

$1.93 +0.05 (+2.66%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$1.90 -0.03 (-1.50%)
As of 09/12/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.